Slingshot members are tracking this event:

Abbvie announced the start of a large Phase 3 clinical trial program to study the use of ABT-494, an investigational, once-daily, oral selective JAK1 inhibitor for the treatment of rheumatoid arthritis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Data from the Phase 2 ABT-494 clinical trials, BALANCE-I and BALANCE-2, announced in September 2015, demonstrated the efficacy of ABT-494 across 6, 12 and 18 mg doses twice-daily, and 24 mg once-daily in RA patients with an inadequate response to prior anti-tumor necrosis factor (TNF-IR) or methotrexate (MTX-IR) treatment. The first two trials out of the five Phase 3 ABT-494 clinical trials have opened for enrollment in the United States. One study will evaluate ABT-494 in combination with MTX in adult patients with moderate to severely active RA who have had an inadequate response to prior treatment with MTX, and will include HUMIRA® (adalimumab) as an active comparator. The second study will include patients who have had an inadequate response or intolerance to conventional synthetic DMARDs. These studies will include assessments of safety and tolerability, as well as key measures of efficacy including ACR responses and levels of disease activity.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 08, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Abt-494, Phase 3, Selective Jak1 Inhibitor, Rheumatoid Arthritis, Ra, Methotrexate-naive Patients, Antirheumatic Drugs, Dmards